# HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

> **NCT05740449** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Princess Maxima Center for Pediatric Oncology**

## Conditions studied

- Acute Lymphoblastic Leukemia, in Relapse
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Venetoclax
- **DRUG:** Navitoclax
- **DRUG:** intrathecal chemotherapy

## Key facts

- **NCT ID:** NCT05740449
- **Lead sponsor:** Princess Maxima Center for Pediatric Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10-01
- **Primary completion:** 2029-10-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company stopped development and production of one of the IMP's.
- **Last updated:** 2024-06-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740449, "HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05740449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*